@misc{indiciae00f02191f724,
  title = {Randomized phase-II trial of surufatinib plus FOLFOX/FOLFIRI versus FOLFOXIRI as second-line therapy for metastatic colorectal cancer.},
  author = {Liyu Su and Peicheng Lin and Yi Yin and Zaisheng Ye and Changhua Zhuo and Shenghong Wei and Shichao Yu and Jinluan Li and Yanni Hong and Liang Zheng and Shen Zhao and Ying Chen and Hui Li and Rongbo Lin},
  year = {2026},
  doi = {10.1080/07853890.2026.2698360},
  url = {https://pubmed.ncbi.nlm.nih.gov/42421558/},
  note = {Source identifier: 42421558}
}